Investors

AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap

ADD Lonsamhet Vit

The share

Chart Bar

Financial reports and presentations

Calendar

Humans

Corporate governance

  • Continued improvement in margins and profit

    The companies within AddLife continue to develop in line with our priorities. Margins are strengthening in both business areas thanks to continuous development of product portfolios and good cost control. Growth was strong in Labtech, and in Medtech, demand was steadily increasing, but was held back somewhat, mainly due to the timing of capital investments in certain countries. Our acquired companies are contributing further to the positive development of margins and growth. Profit for the period  improved by 39 percent in the quarter.

    comments by the ceo
    Fredrik Dalborg Addlife Q2 2025 2

Listen to our latest presentation

 

AddLife creates value

The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.

AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.

ADD Lonsamhet Vit

AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.

ADD Ansvar Vit

AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.

ADD Engagemang Vit

Target fulfilment 2024

Earnings growth

Profitability

Dividend

Contact us!

The investor pages contain all published financial information to facilitate investment decisions.

We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.

Contact: [email protected]

IR- and press contacts

Fredrik Dalborg (2)

Fredrik Dalborg

CEO

[email protected]

Christina Rubenhag

Christina Rubenhag

CFO

[email protected]

Julie Oleary

Julie O'Leary

Investor Relations Manager

[email protected]

Subscribe